Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Share-based Compensation (2020 - 2025)

Vivos Therapeutics' Share-based Compensation history spans 6 years, with the latest figure at $47000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $47000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $764000.0 (down 90.56% YoY), and the annual figure for FY2025 was $661000.0, up 5909.09%.
  • Share-based Compensation for Q4 2025 was $47000.0 at Vivos Therapeutics, down from $100000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.5 million in Q2 2024 to a low of $47000.0 in Q4 2025.
  • The 5-year median for Share-based Compensation is $400000.0 (2022), against an average of $788947.4.
  • The sharpest move saw Share-based Compensation surged 1775.0% in 2024, then plummeted 96.0% in 2025.
  • Year by year, Share-based Compensation stood at $463000.0 in 2021, then surged by 67.39% to $775000.0 in 2022, then tumbled by 81.16% to $146000.0 in 2023, then skyrocketed by 105.48% to $300000.0 in 2024, then tumbled by 84.33% to $47000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $47000.0, $100000.0, and $300000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.